CTNNB1 and Alzheimer disease: CTNNB1 has an overall AD Target Risk Score among the top 10% of all scored targets (score 3.42, rank #2,353) and there is myriad evidence accumulated over the past 25 years of research that links beta-catenin and Wnt signaling, which acts upstream to promote stability of beta-catenin, with amyloid-beta pathology.